NCT05959187View on ClinicalTrials.gov

A Single-center Randomized Controlled Study on the Effect of Pharmacogenomics Trial on Clinical Efficacy in Patients With Depression

NACompletedINTERVENTIONAL
Enrollment

665

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Depressive DisorderPharmacogenomic Drug Interaction
Interventions
DIAGNOSTIC_TEST

pharmacogenomic testing

Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response

Trial Locations (1)

310000

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT05959187 - A Single-center Randomized Controlled Study on the Effect of Pharmacogenomics Trial on Clinical Efficacy in Patients With Depression | Biotech Hunter | Biotech Hunter